Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Nanophotonics Firm Raises $18M in IPO

Facebook Twitter LinkedIn Email Comments
PARIS, Nov. 13, 2012 — Following an initial public offering that raised €14.2 million (about $18 million), a Paris-based nanophotonics company with roots in upstate New York will be listed on the New York Stock Exchange Euronext market.

Nanobiotix — a spinoff founded in 2003 by University of Buffalo postdoctoral researcher Laurent Levy with technology licensed from the university — has developed NanoXray, a nanoparticle-based therapeutic approach for the local treatment of cancer. These nanoparticles enhance the radiotherapy efficacy within cancerous tumors without increasing x-ray-induced damage to surrounding healthy tissue.

While a postdoctoral researcher at UB’s Institute for Lasers, Photonics and Biophotonics, Levy partnered with Roswell Park Cancer Institute and others at UB to develop two technologies: magnetic nanoparticles for the treatment and diagnosis of cancer (nanoMag), and laser-activated nanoparticles for cancer treatment (nanoPDT).

Two licenses obtained from UB allowed him to launch Nanobiotix, Levy said. “We have been able to sublicense part of the applications of those technologies to develop products outside the cancer area. Those technologies will not be the first we will push to market, but have been essential to start our company,” he added.

“It is very satisfying to see the work we are doing in the laboratory have a positive impact on society,” said Dr. Paras Prasad, Levy’s postdoctoral adviser and co-inventor of the nanoMag and nanoPDT technologies. “Early on, Laurent had the foresight to understand the tremendous potential that nanotechnology has to improve the field of medicine.”

The recent IPO funding follows the announcement earlier this year of a deal with Asian firm PharmaEngine that will bring the company up to $57 million and expedite the development of a cancer nanotherapeutic.

For more information, visit:
Nov 2012
AmericasBiophotonicsBusinesscancer therapycancer treatmentEuronextEuropeinitial public offeringIPOlaser-activated nanoparticlesLaurent Levymagnetic nanoparticlesnanoNanobiotixnanoMagnanomedicinenanoPDTnanophotonics spinoffnanotherapeuticNanoXrayNew YorkNew York Stock ExchangeParas PrasadPharmaEngineradiotherapyRoswell Park Cancer InstituteSTORUBUniversity of Buffalo

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2020 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.